August 2019
Procalcitonin (PCT)
Success for Brahms as Radiometer’s nullity suit dismissed
Patent holder Brahms has won the next round in the long-standing dispute over procedures for detecting infections. The Federal Patent Court has dismissed a nullity suit from Radiometer
Read the news on JUVE Patent >
July 2019
Procalcitonin (PCT)
Validity of B·R·A·H·M·S’ patent confirmed by German Federal Patent Court
Again, B·R·A·H·M·S GmbH (B·R·A·H·M·S) has successfully defended one of its many patents relating to Procalcitonin (PCT) in diagnostics and therapy around sepsis and infectious diseases. In a judgment pronounced on 23 July 2019, the German Federal Patent Court confirmed the validity of the German part of B·R·A·H·M·S’ European patent (EP 2 301 626 B1), and completely rejected a revocation action instigated by Radiometer GmbH and Radiometer Medical ApS.
B·R·A·H·M·S’ patent relates to the use of antibiotics in the treatment of a specific group of patients having defined PCT levels. The broad protection conferred by this patent is justified by the fundamental and innovative nature of the patented invention, which has been recognized and acknowledged by the Federal Patent Court’s in its decision to maintain the patent as granted. Because of this the Court held Radiometer liable to pay all court fees and to reimburse the attorney’s fees incurred by B·R·A·H·M·S for its successful defense.
B·R·A·H·M·S welcomes this decision and continues to vigorously defend and enforce its patent rights relating to PCT in Germany and worldwide.
July 2019
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2019.
Thermo Fisher Scientific Reports Second Quarter 2019 Results >
May 2019
Procalcitonin / Health Economics
U.S. Health Economic Analysis Demonstrates the Cost Reduction Impact of using B·R·A·H·M·S PCT to Support Antibiotic Stewardship Versus Standard of Care
Outcome shows a reduction in antibiotic days, shorter length of stay, shorter duration of mechanical ventilation, and fewer patients at risk for antibiotic resistance or C.difficile infection lead to incremental reduction of costs of 26 percent in sepsis and 17.7 percent in lower respiratory tract infection
May 2019
Copeptin / Registration
The novel blood biomarker Copeptin is now available for clinical use in early rule-out of acute myocardial infarction and diagnosing water balance disorders
B·R·A·H·M·S Copeptin proAVP KRYPTOR has been registered in Canada allowing for faster, more reliable indirect measurement of vasopressin to improve diagnostic algorithms
May 2019
Copeptin / Research
European Endocrinology Award 2019 for research about Copeptin
Prof. Christ-Crain gave a lecture on “New diagnostic approaches in the diagnosis of Diabetes insipidus” at the opening ceremony of the ECE 2019, because she received the European Endocrinology Award 2019 for her research about Copeptin.
May 2019
Sepsis / Emergency Department (ED)
New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis
Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department
May 2019
Prenatal screening
World Pre-eclampsia Day on May 22nd
May is Pre-eclampsia awareness month and May 22nd is World Pre-eclampsia Day: Thermo Fisher Scientific proudly supports the pre-eclampsia awareness campaign 2019 organized by EFCNI (European Foundation for the Care of Newborn Infants).
Learn more about World Pre-eclampsia Day >
Pre-eclampsia: First trimester screening >
April 2019
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2019.
Thermo Fisher Scientific Reports First Quarter 2019 Results >
January 2019
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2018.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results >
